Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Kantarjian HM, DeAngelo DJ, Stelljes M, Liedtke M, et al. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Cancer 2019 Mar 28. doi: 10.1002/cncr.32116.
PMID: 30920645

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016